Avanir Pharma announces publication of pivotal phase III results from AVP-825 study
Avanir announced the publication of results from TARGET, a pivotal phase III study evaluating efficacy and safety of AVP-825 22mg in the January 2015 issue of Headache. A NDA for AVP-825 has been accepted and is currently under review by the FDA with a PDUFA date of Nov. 26, 2014. October 30, 2014